BridgeBio Oncology Therapeutics (BBOT) Shares Outstanding (2023 - 2026)

BridgeBio Oncology Therapeutics has reported Shares Outstanding (Entity) for 4 years, with the latest figure at $80032.0 in Q1 2026.

• Quarterly Shares Outstanding (Entity) fell 99.58% year-over-year to $80032.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80032.0 (down 99.58% YoY) and the FY2025 annual result came in at $31.1 million, up 87.22% from the prior year.
• Shares Outstanding (Entity) fell to $80032.0 in Q1 2026 per BBOT's latest filing, from $31.1 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $43.5 million in Q3 2025 and troughed at $80032.0 in Q1 2026.
• A 4-year average of $18.1 million and a median of $18.9 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Entity) soared 261.65% in 2024, then sank 99.58% in 2026.
• Over 4 years, Shares Outstanding (Entity) stood at $4.6 million in 2023, then jumped by 261.65% to $16.6 million in 2024, then surged by 87.22% to $31.1 million in 2025, then plunged by 99.74% to $80032.0 in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $80032.0, $31.1 million, and $43.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.